Hinova Pharmaceuticals, Inc. Class ASSE: 688302

Announcement on Voluntary Disclosure of Obtaining the Drug Clinical Trial Approval Notice for HP518 Tablets, an Oral PROTAC Drug, in Combination with Anti-tumor Therapy for the Treatment of Advanced Prostate Cancer

· Issued by Hinova Pharmaceuticals, Inc. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining the Drug Clinical Trial Approval Notice for HP518 Tablets, an Oral PROTAC Drug, in Combination with Anti-tumor Therapy for the Treatment of Advanced Prostate Cancer

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis